Samy Hamdouche, PhDinMission.orgHow I Beat the Market in 2017A Year-End Review of My Biotech StrategyJan 8, 20183Jan 8, 20183
Samy Hamdouche, PhDinMission.orgThe World’s Most Essential DrugHow Placebo Can Be a Self-Fulfilling PrescriptionNov 30, 20175Nov 30, 20175
Samy Hamdouche, PhDinMission.orgTrade Biotech Stocks Like a Hedge Fund With These HacksWe dance round in a ring and suppose,Sep 11, 20173Sep 11, 20173
Samy Hamdouche, PhDZogenix: The proof is in the publications“Men occasionally stumble over the truth, but most of them pick themselves up and hurry off as if nothing ever happened” — Winston…Aug 21, 20171Aug 21, 20171
Samy Hamdouche, PhDinMission.orgThe Wild World of Biotech Insider Trading“Lesson number one: Don’t underestimate the other guy’s greed.” — ScarfaceAug 17, 20175Aug 17, 20175
Samy Hamdouche, PhDFMX-101: Persistence pays off“My ability to turn good news into anxiety is rivaled only by my ability to turn anxiety into chin acne” — Tina FeyJul 13, 20171Jul 13, 20171
Samy Hamdouche, PhDSAGE-547: Fooling some of the people all of the time“Why don’t you slip into something more comfortable… like a coma” — Jerry LawlerApr 25, 2017Apr 25, 2017
Samy Hamdouche, PhDOCR-002: When a drug fails, but actually worksOcera Therapeutics (OCRX) is a clinical stage biopharmaceutical company, focused primarily on developing OCR-002 (ornithine phenylacetate)…Mar 21, 2017Mar 21, 2017